Saturday, 21 June 2025
  
Login

Australia's most trusted
source of pharma news

Saturday, 21 June 2025
News

Novartis drug to dominate sector

Posted 20 June 2025 AM

Novartis' Pluvicto will dominate the radioligand therapy sector for years, according to a new report on up-and-coming companies seeking to get into the market.

The Swiss company has spent the most on radioligands, dropping around $9.2 billion (US$6 billion) to acquire theranostic expertise and assets, notes Clarivate in its report Radioligand Innovators Ushering in a New Era of Precision Oncology: Companies to Watch 2025.

To see the whole article, please login

Popular

Five MDs to talk at new event
Who's relocated to the CBD?
Pharma moves into OTC market
Novartis drug to dominate sector
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (9)

Clinical & Medical, R&D (13)

Regulatory, Pharmacovigilance & QA (3)

Other (12)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home